A risk-adapted approach to the use of radioactive iodine and external beam radiation in the treatment of well-differentiated thyroid cancer

Cancer Control

Volumn 18, Issue 2, 2011, Pages 89-95

  Tuttle, R Michael ^a   Rondeau, Geneviève ^a   Lee, Nancy Y ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE; RADIOACTIVE IODINE;

ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DISTANT METASTASIS; DOSE RESPONSE; DRUG SAFETY; ESOPHAGUS STRICTURE; EXTERNAL BEAM RADIOTHERAPY; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LEUKOCYTE COUNT; LOCAL METASTASIS; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; METASTASIS; METASTASIS RESECTION; PHARYNGITIS; RADIATION DOSE; RADIOFREQUENCY ABLATION; RECURRENT DISEASE; REGIONAL METASTASIS; REPEATED DRUG DOSE; RISK ASSESSMENT; SALIVA; SALIVARY GLAND DISEASE; SIDE EFFECT; SKIN FIBROSIS; THROMBOCYTE COUNT; THYROID CANCER; THYROIDECTOMY; TRACHEA STENOSIS; TREATMENT INDICATION; TUMOR DIFFERENTIATION; XEROSTOMIA;

EID: 79954480769     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481101800203     Document Type: Article

References (22)

1. Hay ID. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol. 2006;94(8):692-700.
2. Mazzaferri EL. Management of low-risk differentiated thyroid cancer. Endocr Pract. 2007;13(5):498-512.
3. Tuttle RM. Risk-adapted management of thyroid cancer. Endocr Pract. 2008;14(6):764-774.
4. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-1214.
5. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York, New York: Springer-Verlag; 2002.
6. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114(6):1050-1057; discussion 1057-1058.
7. Tuttle RM. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™): Thyroid Cancer. http://www.nccn.org/professionals/physician_ gls/PDF/thyroid.pdf. Accessed April 8, 2010.
8. Tuttle RM, Lopez N, Leboeuf R, et al. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Thyroid. 2010;20(3):257-263.
9. Lee N, Tuttle M. The role of external beam radiotherapy in the treatment of papillary thyroid cancer. Endocr Relat Cancer. 2006;13:971-977.
10. Brierley JD, Tsang RW. External beam radiation therapy for thyroid cancer. Endocrinol Metab Clin North Am. 2008;37(2):497-509 xi. Review.
11. Sawka AM, Brierley JD, Tsang RW, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am. 2008;37(2):457-480
12. Brown AP, Chen J, Hitchcock YJ, et al. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab. 2008;93(2):504-515.
13. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003;89(9):1638-1644.
14. Sawka AM, Thabane L, Parlea L, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid. 2009;19(5):451-457.
15. Grewal RK, Larson SM, Pentlow CE, et al. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. J Nucl Med. 2009;50(10):1605-1610.
16. Molinaro E, Leboeuf R, Shue B, et al. Mild decreases in white blood cell and platelet counts are present one year after radioactive iodine remnant blation. Thyroid. 2009;19(10):1035-1041.
17. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 atients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892-2899.
18. Robbins RJ, Wan Q, Grewal RK, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006;91(2):498-505.
19. Tuttle RM, Brokhin M, Omry G, et al. Recombinant human TSHassisted adioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med. 2008;49(5):764-770.
20. Strasser JF, Raben A, Koprowski C. The role of radiation therapy in the management of thyroid cancer. Surg Oncol Clin N Am. 2008;17(1):219- 232, x.
21. Terezakis SA, Lee KS, Ghossein RA, et al. Role of external beam adiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys. 2009;73(3):795-801.
22. Mazzarotto R, Cesaro MG, Lora O, et al. The role of external beam radiotherapy in the management of differentiated thyroid cancer. Biomed Pharmacother. 2000;54(6):345-349.